Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640431 | 0.83 | FAAH (0.51) | HPGDFAAHMGLL | |
| SCHEMBL5967969 | 0.82 | MGLL (0.46) | ALDH1A1HPGDRAB9AFAAHMGLL | |
| SCHEMBL5641990 | 0.81 | FAAH (0.47) | ALDH1A1KDM4EHPGDMAPTRAB9A | |
| SCHEMBL5642585 | 0.81 | FAAH (0.48) | ALDH1A1KDM4EHPGDMAPTRAB9A | |
| SCHEMBL5640188 | 0.81 | MGLL (0.49) | HPGDMAPTRAB9AFAAHMGLL | |
| SCHEMBL5639724 | 0.78 | FAAH (0.45) | ALDH1A1HPGDRAB9AFAAHMGLL | |
| SCHEMBL5642345 | 0.78 | MGLL (0.55) | ALDH1A1HPGDMAPTFAAHMGLL | |
| SCHEMBL5641596 | 0.78 | FAAH (0.67) | FAAHMGLL | |
| SCHEMBL5642119 | 0.77 | MGLL (0.55) | ALDH1A1HPGDRAB9AFAAHMGLL | |
| SCHEMBL3024500 | 0.75 | MGLL (0.48) | LMNAHPGDRAB9AFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-7208504-B2 | Bicyclic inhibitors of hormone sensitive lipase | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-24 | — | — | US | disclosed |
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127484-A1 | Novel bicyclic inhibitors of hormone sensitive lipase | LIPE, PNLIP, CEL | ALDH1A1 636/4885KDM4E 2337/4885LMNA 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.